H1N1 Influenza Clinical Trial
Official title:
Evolution of Serum and Bronchoalveolar Inflammatory Parameters in Patients With Severe Adult Respiratory Distress Syndrome (ARDS) Without or With Extracorporeal Mechanical Assistance
Mannose-binding lectin (MBL) plays an important role in the innate immune response. In addition to activating the complement, MBL can induce cytokine production and contribute to a deleterious inflammatory response with severe A(H1N1)pdm09 virus infection. The aim was to determine if serum MBL levels correlate with the risk of mortality in intensive care units (ICU) patients with A(H1N1)pdm09 infection. Prospective observational study was performed in ICU patients with acute respiratory distress syndrome due to influenza A(H1N1)pdm09 virus. Demographic characteristics and severity indices were recorded at ICU admission. MBL was assayed from blood drawn at influenza diagnosis within 24-48 h following the ICU admission. Outcomes were compared according to MBL levels.
Mannose-binding lectin (MBL) plays an important role in the innate immune response. In addition to activating the complement, MBL can induce cytokine production and contribute to a deleterious inflammatory response with severe A(H1N1)pdm09 virus infection. The aim was to determine if serum MBL levels correlate with the risk of mortality in intensive care units (ICU) patients with A(H1N1)pdm09 infection. Prospective observational study was performed in ICU patients with acute respiratory distress syndrome due to influenza A(H1N1)pdm09 virus. Demographic and clinical data at admission and during the ICU stay were recorded from the medical files of each patient and collected in a database to evaluate variables potentially associated with in-hospital mortality. Data baselines were recorded at admission. Mechanical ventilation, extracorporeal membrane oxygenation (ECMO) requirements, and the use of vasopressor drugs were noted during ICU stay. To determine illness severity, SAPSII and SOFA scoring systems were applied to all patients within 24 h of ICU admission.Demographic characteristics and severity indices were recorded at ICU admission. MBL was assayed from blood drawn at influenza diagnosis within 24-48 h following the ICU admission. Outcomes were compared according to MBL levels. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00970606 -
STIP: Statin Trial for Influenza Patients
|
N/A | |
| Completed |
NCT02921997 -
H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses
|
Phase 2 | |
| Recruiting |
NCT01008683 -
Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation
|
N/A | |
| Completed |
NCT01011582 -
Characteristics and Outcomes of Intensive Care Unit Patients Admitted With Novel H1N1 Influenza or Seasonal Influenza
|
N/A | |
| Active, not recruiting |
NCT01421251 -
H1N1 Vaccine Safety in Manitoba, Canada
|
N/A | |
| Recruiting |
NCT04497311 -
Tomographic Findings in COVID-19 and Influenza
|
||
| Completed |
NCT04933994 -
Comparison of COVID-19 and H1N1 Influenza Pneumonia
|
||
| Completed |
NCT01002040 -
Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV
|
Phase 4 | |
| Unknown status |
NCT01127282 -
The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A
|
Phase 4 | |
| Terminated |
NCT01798602 -
Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial
|
Phase 2 | |
| Terminated |
NCT04810949 -
Vitamine D3 Supplementation in Patients With Serum Values +/- 20ng/ml
|
N/A | |
| Completed |
NCT05080933 -
ECMO for COVID-19 vs Influenza A H1N1 Associated ARDS
|